Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)
Brief description of study
The purpose of the study is to see how well the study drug, pembrolizumab, works compared to placebo in keeping your cancer from coming back or spreading. The study is also being done to test the safety of the study drug and to see how well your body handles the study drug.
Clinical Study Identifier: s18-00312
ClinicalTrials.gov Identifier: NCT03553836
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
